Envestnet Asset Management Inc Vir Biotechnology, Inc. Transaction History

Envestnet Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$23.2 - $27.29 $6.79 Million - $7.98 Million	-292,517 Reduced 84.95%	51,827 $1.27 Million
Q1 2023 May 11, 2023	BUY	$22.26 - $30.85 $6.55 Million - $9.08 Million	294,390 Added 589.32%	344,344 $8.01 Million
Q4 2022 Feb 07, 2023	BUY	$19.96 - $28.22 $94,470 - $133,565	4,733 Added 10.47%	49,954 $1.26 Million
Q3 2022 Nov 10, 2022	BUY	$18.26 - $31.1 $664,170 - $1.13 Million	36,373 Added 411.09%	45,221 $872,000
Q2 2022 Aug 03, 2022	BUY	$19.08 - $26.7 $168,819 - $236,241	8,848 New	8,848 $225,000
Q1 2022 May 04, 2022	SELL	$21.19 - $40.01 $144,918 - $273,628	-6,839 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$30.97 - $54.03 $211,803 - $369,511	6,839 New	6,839 $286,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.